Table 3.
Snapshot of forthcoming therapies
| Drug category | Emerging drugs for myeloma |
|---|---|
| PI | Oprozomib |
| Marizomib | |
| HDACi | Ricolinostat |
| Monoclonal antibody | Indatuximab ravtansine |
| BT062 | |
| GSK2857916 | |
| Bion 1301 | |
| MOR202 | |
| Isatuximab | |
| BB10901 | |
| IL-6 inhibitor | Siltuximab |
| HIV protease inhibitor | Nelfinavir |
| Wnt inhibitor | CWP291 |
| EZH2 inhibitor | GSK2816126 |
| Radioisotope | I 131 CLR1404 |
| KSP inhibitor | Filanesib |
| Hypomethylation of DNA | Azacitidine |
| Hypoxia activated | Evofosfamide |
| SINE | Selinexor, KPT-8602 |
| Virus | Reolysin |
| CTLA-4 inhibitor | Ipilimumab |
| BTK inhibitor | Ibrutinib |
| AKT inhibitor | Afuresertib |
| Checkpoint inhibitors | Pembrolizumab, nivolumab |
| MEK inhibitor | Trametinib |
| Bcl-2 inhibitor | Venetoclax |
| Oncolytic virus | Oncolytic reovirus |
| CAR T-cells | CTL019 cells |
| NKG2D | |
| SLAMF7-CAR T-cell | |
| TCRt | |
| BiTE | AMG 420 |
Abbreviations: AKT, protein kinase B; Bcl-2, B-cell lymphoma 2; BiTE, bispecific T-cell engager; BTK, Bruton’s tyrosine kinase; CAR, chimeric antigen receptor; CTLA-4, cytotoxic T-lymphocyte-associated protein 4; EZH2, enhancer of zeste homolog 2; HDACi, histone deacetylase inhibitor; HIV, human immunodeficiency virus; IL, interleukin; KSP, kinesin spindle protein; MEK, mitogen-activated protein kinase; PI, proteasome inhibitor; SINE, selective inhibitor of nuclear export; SLAM, signaling lymphocytic activation molecule; SLAMF7, self-ligand receptor of the SLAM family member 7; SYK, spleen tyrosine kinase; TCRt, T-cell receptor-modified T-cells.